Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Date:6/3/2008

- Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965

E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

5

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Dynatronics Receives 180-Day NASDAQ Extension 2Negative Pressure Wound Devices Draw FDA Notice, Advice 2DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 60296 1BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 60296 2BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 60296 3BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 60296 4BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 60296 5BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 60296 6BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 60296 7BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 60296 8BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 60296 9BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 60296 10BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 60296 11BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 60296 12BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 60296 13BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 60296 14BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results 60296 15House Judiciary Committee Hearing Calls Attention to Long Term Effects of Head Injury Among NFL Players 60291 1House Judiciary Committee Hearing Calls Attention to Long Term Effects of Head Injury Among NFL Players 60291 2Praxis Electronic Medical Records Announces New Version 5 With Breakthrough in EHR Documentation 5806 1Praxis Electronic Medical Records Announces New Version 5 With Breakthrough in EHR Documentation 5806 2